Flixotide Inhaler CFC-Free 250 Micrograms - Fluticasone Propionate

Flixotide Inhaler CFC-Free 250 Micrograms - Fluticasone Propionate

Product Description:
Flixotide Inhaler CFC-Free 250 Micrograms is a corticosteroid inhalation medication containing Fluticasone Propionate, designed for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). This inhaler provides anti-inflammatory action, reducing the swelling and irritation in the walls of the small air passages in the lungs, and thus easing breathing difficulties.

Technical Specifications:
- Active Ingredient: Fluticasone Propionate 250 micrograms per actuation
- Delivery: Metered-dose inhaler
- Formulation: CFC-Free propellant for environmental compliance
- Dosage: Typically one inhalation twice a day (doctor's prescription is advised)
- Container: Aluminum canister with a metering valve
- Shelf Life: Check packaging for expiry date
- Storage: Store below 30°C; do not freeze

Common Applications/User Groups:
- Asthma Patients: Individuals diagnosed with mild to severe asthma using it as a preventative treatment.
- COPD Patients: Those managing chronic obstructive pulmonary disease symptoms.
- Long-term Management: Suitable for long-term use to control persistent symptoms.
- Adults and Children: Indicated for adults and children with a prescription, with the dosage adjusted accordingly.

Supplier Overview - GSK (GlaxoSmithKline):
GlaxoSmithKline (GSK) is a leading global healthcare company with a robust commitment to improving the quality of human life by enabling people to do more, feel better, and live longer. With a long-standing heritage in respiratory care, GSK has established itself as an authority in the development and production of inhalation products. Their dedication to innovation, rigorous scientific research, and patient safety makes them a trusted supplier in the pharmaceutical industry. GSK's expertise in the respiratory product category, including the Flixotide Inhaler, is supported by a wide range of successful treatments and a continuous investment in new technologies and research to meet the evolving needs of patients with respiratory conditions.